Literature DB >> 26335533

Evaluation of Polymeric Nanomedicines Targeted to PSMA: Effect of Ligand on Targeting Efficiency.

Adrian V Fuchs, Brian W C Tse1, Amanda K Pearce, Mei-Chun Yeh1, Nicholas L Fletcher, Steve S Huang2, Warren D Heston3, Andrew K Whittaker, Pamela J Russell1, Kristofer J Thurecht.   

Abstract

Targeted nanomedicines offer a strategy for greatly enhancing accumulation of a therapeutic within a specific tissue in animals. In this study, we report on the comparative targeting efficiency toward prostate-specific membrane antigen (PSMA) of a number of different ligands that are covalently attached by the same chemistry to a polymeric nanocarrier. The targeting ligands included a small molecule (glutamate urea), a peptide ligand, and a monoclonal antibody (J591). A hyperbranched polymer (HBP) was utilized as the nanocarrier and contained a fluorophore for tracking/analysis, whereas the pendant functional chain-ends provided a handle for ligand conjugation. Targeting efficiency of each ligand was assessed in vitro using flow cytometry and confocal microscopy to compare degree of binding and internalization of the HBPs by human prostate cancer (PCa) cell lines with different PSMA expression status (PC3-PIP (PSMA+) and PC3-FLU (PSMA-). The peptide ligand was further investigated in vivo, in which BALB/c nude mice bearing subcutaneous PC3-PIP and PC3-FLU PCa tumors were injected intravenously with the HBP-peptide conjugate and assessed by fluorescence imaging. Enhanced accumulation in the tumor tissue of PC3-PIP compared to PC3-FLU highlighted the applicability of this system as a future imaging and therapeutic delivery vehicle.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26335533     DOI: 10.1021/acs.biomac.5b00913

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  7 in total

1.  Development and Application of a Novel Model System to Study "Active" and "Passive" Tumor Targeting.

Authors:  Amarnath Mukherjee; Binod Kumar; Koji Hatano; Luisa M Russell; Bruce J Trock; Peter C Searson; Alan K Meeker; Martin G Pomper; Shawn E Lupold
Journal:  Mol Cancer Ther       Date:  2016-08-02       Impact factor: 6.261

2.  Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand.

Authors:  Stefano Boschi; Jason T Lee; Seval Beykan; Roger Slavik; Liu Wei; Claudio Spick; Uta Eberlein; Andreas K Buck; Filippo Lodi; Gianfranco Cicoria; Johannes Czernin; Michael Lassmann; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-22       Impact factor: 9.236

3.  111In- and IRDye800CW-Labeled PLA-PEG Nanoparticle for Imaging Prostate-Specific Membrane Antigen-Expressing Tissues.

Authors:  Sangeeta R Banerjee; Catherine A Foss; Allen Horhota; Mrudula Pullambhatla; Kevin McDonnell; Stephen Zale; Martin G Pomper
Journal:  Biomacromolecules       Date:  2016-12-21       Impact factor: 6.988

Review 4.  Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo.

Authors:  Amanda K Pearce; Adrian V Fuchs; Nicholas L Fletcher; Kristofer J Thurecht
Journal:  Pharm Res       Date:  2016-05-25       Impact factor: 4.200

Review 5.  Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular Imaging.

Authors:  Leila Hassanzadeh; Suxiang Chen; Rakesh N Veedu
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-15

6.  KLK4 Induces Anti-Tumor Effects in Human Xenograft Mouse Models of Orthotopic and Metastatic Prostate Cancer.

Authors:  Brian W-C Tse; Thomas Kryza; Mei-Chun Yeh; Ying Dong; Kamil A Sokolowski; Carina Walpole; Tobias Dreyer; Johanna Felber; Jonathan Harris; Viktor Magdolen; Pamela J Russell; Judith A Clements
Journal:  Cancers (Basel)       Date:  2020-11-24       Impact factor: 6.639

7.  Heterogeneous PSMA expression on circulating tumor cells: a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer.

Authors:  Tobias M Gorges; Sabine Riethdorf; Oliver von Ahsen; Paulina Nastał Y; Katharina Röck; Marcel Boede; Sven Peine; Andra Kuske; Elke Schmid; Christoph Kneip; Frank König; Marion Rudolph; Klaus Pantel
Journal:  Oncotarget       Date:  2016-06-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.